Topping tamoxifen as 1st-line Rx for postmenopausal breast Ca

Article

Aromatase inhibitors should replace tamoxifen as the first choice for preventing recurrence of breast cancer in postmenopausal women with localized hormone receptor-positive disease, according to this large-scale study.

Newsletter

Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.

Recent Videos
Thomas McElrath, MD, PhD, highlights limitations of current preeclampsia guidelines | Image Credit: physiciandirectory.brighamandwomens.org.
Jane Varney, MD, discusses how a low FODMAP diet mediates gut symptoms caused by endometriosis | Image Credit: lens.monash.edu.
Ousseny Zerbo, PhD, highlights benefits of influenza vaccination during pregnancy | Image Credit: divisionofresearch.kaiserpermanente.org.
Michael Ussher, PhD, highlights the benefits of vaping over smoking in pregnancy | Image Credit: sgul.ac.uk.
Neal Barnard, MD, FACC, highlights AMA's new breast cancer prevention guidelines | Image Credit: pcrm.org.
Related Content
© 2025 MJH Life Sciences

All rights reserved.